| Ytd | -26.15% | |
| 1y | -60.70% |
| Open | 0.55 | Prev Close | 0.55 | Low | 0.55 | High | 0.58 | Mkt Cap | 6.10M |
| Vol | 123.28K | Avg Vol | 637.86K | EPS | -2.57 | P/E | -0.21 | Forward P/E | 15.32 |
| Beta | 0.98 | Short Ratio | 1.23 | Inst. Own | 13.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.59 | 200-d Avg | 0.89 | 1yr Est | 54.00 |
CTXR News
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. b
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. b
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutic
Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncolo
24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and f
HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Citius Pharmaceuticals (NASDAQ:CTX
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $
$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ® Citiu
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distr
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius P
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biop
Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after the company announced a register
Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius P
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribin
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribin
Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get
Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinica
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutic
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LY
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonst
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonst
Non-dilutive capital supports continued execution and value creation CRANFORD, N.J., Feb. 24, 2026 /
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.38) per share which missed the analyst
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides f
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides f
Third international distribution agreement further advances global access strategy with major market
PainReform (NASDAQ: PRFX - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Repo
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get
(Editor’s note: The future prices of benchmark tracking ETFs and headline were updated in the story.
Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPH
U.S. stock futures slightly lower. UiPath joins S&P Midcap 400, Agios receives FDA approval, Can
On Tuesday, 386 stocks made new 52-week lows.
Gainers Biodexa Pharmaceuticals (NASDAQ: BDRX) shares rose 76% to $0.8276 in pre-market trading a